Xi'an Medical University, Xi'an, China.
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):46-56. doi: 10.1038/s41575-023-00846-4. Epub 2023 Oct 5.
Recompensation has gained increasing attention in the field of cirrhosis, particularly in chronic liver disease with a definite aetiology. The current global prevalence of obesity and nonalcoholic fatty liver disease (NAFLD) is increasing, but there is currently a lack of a clear definition for recompensation in NAFLD-related cirrhosis. Here, we provide an up-to-date perspective on the natural history of NAFLD, emphasizing the reversible nature of the disease, summarizing possible mechanisms underlying recompensation in NAFLD, discussing challenges that need to be addressed and outlining future research directions in the field. Recompensation is a promising goal in patients with NAFLD-related cirrhosis, and further studies are needed to explore its underlying mechanisms and uncover its clinical features.
补偿在肝硬化领域受到越来越多的关注，特别是在有明确病因的慢性肝病中。目前，肥胖和非酒精性脂肪性肝病（NAFLD）的全球患病率正在上升，但目前对于 NAFLD 相关肝硬化的补偿尚无明确定义。在这里，我们提供了 NAFLD 自然史的最新观点，强调了疾病的可逆性，总结了 NAFLD 中补偿的可能机制，讨论了需要解决的挑战，并概述了该领域的未来研究方向。补偿是 NAFLD 相关肝硬化患者的一个有前途的目标，需要进一步研究来探索其潜在机制并揭示其临床特征。
